Catalog No.
DHC80029
Expression system
Mammalian Cells
Species reactivity
Human
Clonality
Monoclonal
Target
GAA, Lysosomal alpha-glucosidase, Acid maltase, Aglucosidase alfa
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Ion Exchange Chromatography.
Accession
P10253
Applications
Research Grade Biosimilar
Form
Lyophilized
Storage buffer
Lyophilized from PBS pH7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Myozyme
Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis, PMID: 27372449
A randomized study of alglucosidase alfa in late-onset Pompe's disease, PMID: 20393176
Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study, PMID: 30770310
Alglucosidase Alfa, PMID: 30000880
Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature, PMID: 31904026
The emerging phenotype of late-onset Pompe disease: A systematic literature review, PMID: 28185884
Gene Therapy for Pompe Disease: The Time is now, PMID: 31298581
Pre/post effectiveness evaluation of updated additional risk minimisation measures for an orphan disease: Myozyme (alglucosidase alfa) Safety Information Packet, PMID: 31667955
Pompe disease: early diagnosis and early treatment make a difference, PMID: 23632029
Structure of human lysosomal acid α-glucosidase-a guide for the treatment of Pompe disease, PMID: 29061980
Recent developments, utilization, and spending trends for pompe disease therapies, PMID: 24991319
Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease, PMID: 28648663
Alglucosidase alfa and Pompe disease: still going strong?, PMID: 23034445
Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network, PMID: 32354651
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease, PMID: 19287243
Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry, PMID: 32515844
Unwarranted, long term, alglucosidase alfa enzyme replacement therapy in two non-Pompe disease patients, PMID: 32623214
Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa, PMID: 23031366
Alglucosidase alfa therapy for Pompe disease in pregnancy - Case report, PMID: 28320122
Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial, PMID: 19649685
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease, PMID: 29237491
Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study, PMID: 26768149
Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study, PMID: 29565424
An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions, PMID: 21802969
Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease, PMID: 25617983
Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation, PMID: 27692944
Identification of Undetected Monogenic Cardiovascular Disorders, PMID: 32792077
High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa, PMID: 20826098
Improved efficacy of a next-generation ERT in murine Pompe disease, PMID: 30843882
Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III, PMID: 23318145
Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa, PMID: 19640753
Glycogen storage disease types I and II: treatment updates, PMID: 17308886
Acid alpha-glucosidase deficiency (Pompe disease), PMID: 17217857
Lysosomal storage diseases, PMID: 18720909
Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study, PMID: 27473031
Therapeutic approaches in glycogen storage disease type II/Pompe Disease, PMID: 19019308
Two successfully completed pregnancies in adult onset Pompe disease, under continued treatment with alglucosidase alfa, PMID: 30715719
Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa, PMID: 25210119
Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation, PMID: 29289479
Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease, PMID: 19542901
Immunomodulatory, liver depot gene therapy for Pompe disease, PMID: 29295737
[Which follow-up for innovative treatments?], PMID: 30943166
Feasibility Study for Bedside Production of Recombinant Human Acid α-Glucosidase: Technical and Financial Considerations, PMID: 32065100
[Pompe's disease], PMID: 18029059
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease, PMID: 24884717
36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy, PMID: 22290025
Massive parallel sequencing of dried umbilical cord remnants, PMID: 32902111
Diagnosis and management of Pompe disease, PMID: 25118547
Enzyme replacement therapy with alglucosidase alfa in a late-onset Pompe disease patient during pregnancy, PMID: 30314719
FDA balks at Myozyme scale-up, PMID: 18536660
For research use only. Not for human or drug use.
